Parkinson's Disease Clinical Trial Tracker — Stay Ahead of the PD Pipeline

Why Parkinson's disease trial monitoring matters

Parkinson's disease is one of the most active areas in neurology drug development, with hundreds of active trials on ClinicalTrials.gov spanning disease modification, symptomatic relief, and emerging modalities including gene therapy and cell-based approaches. The pipeline has accelerated significantly as alpha-synuclein biology, LRRK2 inhibition, and GBA1 pathways have matured as targets.

Key signals that Parkinson's professionals track:

• New neuroprotective and disease-modifying programs targeting alpha-synuclein aggregation, LRRK2 inhibition, and mitochondrial dysfunction
• GBA1-positive patient subpopulation trials as precision medicine approaches advance
• Gene therapy programs (AAV-based) entering Phase 1/2 first-in-human studies
• Non-motor symptom trials (cognitive decline, depression, autonomic dysfunction)
• Status changes: trials beginning to recruit or advancing from Phase 2 to Phase 3
• Competitive pipeline updates from major CNS-focused sponsors

What DataLookout monitors for Parkinson's disease

DataLookout pulls directly from the ClinicalTrials.gov API every day. For a Parkinson's watch profile, you can configure:

• Condition keywords: "Parkinson's disease", "Parkinson disease", "PD", "LRRK2", "GBA1", "alpha-synuclein", "synucleinopathy", "Lewy body"
• Phase filter: Early Phase 1, Phase 2, Phase 2/3, or pivotal Phase 3 trials only
• Sponsor filter: Industry-sponsored programs (competitive intelligence) or all sponsors including NIH, Michael J. Fox Foundation-funded academic studies
• Status filter: Recruiting only, all active studies, or any status including completed/terminated

How it compares to ClinicalTrials.gov RSS alerts

ClinicalTrials.gov has basic email notifications, but they fall short for professional neurodegeneration monitoring:

• No phase filtering — early Phase 1 pilot studies appear alongside major Phase 3 outcomes trials
• No sponsor type filtering — academic observational studies and Michael J. Fox Foundation trials mix with industry BD-relevant programs
• No clear distinction between new registrations and routine record amendments
• No ability to run parallel profiles for different target mechanisms simultaneously
• Designed for patient use, not professional pipeline tracking

DataLookout delivers filtered, labeled, and organized daily alerts — the professional intelligence layer on top of ClinicalTrials.gov data.

Who uses Parkinson's disease trial monitoring

Neurology pharma business development teams

BD teams at CNS-focused pharmaceutical companies track the emerging Parkinson's pipeline to identify licensing, co-development, and acquisition opportunities. A new Phase 1 alpha-synuclein antibody program from a well-capitalized biotech is material intelligence. Knowing the day it's registered — and being able to track its progression — gives BD teams a competitive edge.

Biotech investors and CNS-focused analysts

Investors covering neurology track clinical trial registrations as leading indicators of pipeline advancement. A Phase 3 initiation in a validated target like LRRK2 inhibition can precede a major financing event or partnership announcement by many months.

Clinical research organizations (CROs) with neurology practices

CROs specializing in neurology track new PD trial registrations to identify programs entering the active clinical phase — sponsors who will need site selection, patient recruitment, and data management support for complex CNS trials.

Patient advocacy organizations and foundations

Organizations like the Parkinson's Foundation and Michael J. Fox Foundation track new recruiting trials to connect patients with relevant clinical trial opportunities and monitor the overall health of the research pipeline.

Frequently asked questions

How current is the Parkinson's disease trial data?

Our pipeline fetches from ClinicalTrials.gov every morning. Studies posted or updated in the preceding 24 hours appear in that day's digest. ClinicalTrials.gov is updated continuously as sponsors register new studies or submit protocol amendments.

Can I track disease-modifying and symptomatic trials separately?

Yes. On the Pro plan ($129/month), you can create up to 5 separate search profiles. For example: one profile for disease-modifying programs (alpha-synuclein, LRRK2, GBA1 keywords), another for symptomatic relief trials, and a third for gene/cell therapy first-in-human studies.

Does DataLookout cover atypical parkinsonism — PSP, MSA, LBD?

Yes — you can configure keywords for progressive supranuclear palsy (PSP), multiple system atrophy (MSA), Lewy body dementia (LBD), and corticobasal syndrome. These related synucleinopathies are all registered on ClinicalTrials.gov and searchable within the same platform.

Does DataLookout cover international Parkinson's disease trials?

ClinicalTrials.gov includes internationally conducted trials when the sponsor registers them. Major industry-sponsored Phase 2/3 PD trials, which frequently include European and global sites, are generally registered and included.